Nuclear Medicine Market Size & Growth Forecast 2027–2036, By Segments (Product, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Nuclear Medicine Market size was assessed at USD 24.1 billion in 2026 and is poised to grow at a 6.46% CAGR between 2027 and 2036, exceeding USD 45.07 billion by 2036. The industry revenue for 2027 is calculated at USD 25.41 billion.
Get more details on this report
Request Free Sample ReportNuclear Medicine Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with a 45.44% share, supported by advanced healthcare infrastructure, widespread diagnostic and therapeutic procedures, and strong radioisotope supply and clinical networks across hospitals and specialty centers.
- Asia Pacific growth at 13.1% CAGR is driven by rising healthcare investment, expanded access to diagnostic imaging, and increasing adoption of radiopharmaceutical therapies across developing hospital systems.
Segment Momentum
- Diagnostics held a 73.49% share in 2026 due to their widespread use in disease detection, staging, and treatment monitoring, making them a routine component of clinical and imaging workflows.
- Hospitals held a 57.75% market share in 2026 and are growing fastest because they combine imaging infrastructure, radiopharmaceutical management, multidisciplinary care, and patient monitoring within a single setting.
Market Expansion Drivers
- Rising global cancer burden increasing demand for targeted radiopharmaceutical diagnostics and therapies.
- Expansion of theranostics and precision oncology improving nuclear medicine clinical adoption rates.
- Favorable reimbursement policies and government funding expanding access to radiopharmaceutical treatments.
Leading Market Participants
- Key companies in the nuclear medicine market include GE HealthCare Technologies Inc. (United States), Cardinal Health, Inc. (United States), Lantheus Holdings, Inc. (United States), Bracco Imaging S.p.A. (Italy), Mallinckrodt plc (Ireland), Eckert & Ziegler SE (Germany), Nordion Inc. (Canada), Curium Pharma (France), Jubilant Pharmova Limited (India), Eczacıbaşı-Monrol Nuclear Products Co. (Turkey).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 24.1 billion
- 2027 Estimated Market Size: USD 25.41 billion.
- Projected Market Size: USD 45.07 billion by 2036
- Growth Forecast: 6.46% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Diagnostics (Product) | Hospitals (End Use) | Urology (Application)
- Emerging Opportunity Segment: Therapeutics (Product) | Hospitals (End Use) | Urology (Application)
Market Growth Drivers and Industry Trends
Rising global cancer burden increasing demand for targeted radiopharmaceutical diagnostics and therapies
The increasing prevalence of cancer is strengthening demand for diagnostic and therapeutic approaches that can identify disease sites and deliver treatment with greater precision. The nuclear medicine market will benefit from this trend as radiopharmaceuticals enable targeted imaging and therapies for various cancer-related applications. Greater emphasis on earlier detection and more precise treatment selection is increasing the role of nuclear medicine within oncology care pathways.
Expansion of theranostics and precision oncology improving nuclear medicine clinical adoption rates
The integration of diagnostic imaging and targeted treatment through theranostics is expanding the clinical applications of nuclear medicine in precision oncology. Advances in this approach will propel the nuclear medicine market as clinicians can use molecular characteristics identified through imaging to guide the selection of targeted radiopharmaceutical therapies. Increasing focus on individualized treatment strategies is also encouraging broader clinical utilization of nuclear technologies across cancer diagnosis, patient selection, and treatment monitoring.
Favorable reimbursement policies and government funding expanding access to radiopharmaceutical treatments
Supportive reimbursement frameworks and government funding can improve the affordability and availability of radiopharmaceutical-based procedures across healthcare systems. Favorable policies will drive nuclear medicine market demand by reducing financial barriers for healthcare providers and patients seeking specialized diagnostic and therapeutic services. Public investment can also support the development of nuclear medicine infrastructure, treatment facilities, and broader access to radiopharmaceutical technologies.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer burden increasing demand for targeted radiopharmaceutical diagnostics and therapies | 2.40% | High | North America, Europe | High | Near Term |
| Expansion of theranostics and precision oncology improving nuclear medicine clinical adoption rates | 2.00% | High | North America, Asia Pacific | High | Mid Term |
| Favorable reimbursement policies and government funding expanding access to radiopharmaceutical treatments | 1.80% | High | North America, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The nuclear medicine market was led by North America, which accounted for a 45.44% share in 2026, supported by advanced healthcare infrastructure, broad availability of specialized diagnostic and therapeutic services, and strong adoption of sophisticated medical technologies. Established nuclear medicine capabilities and continued investment in precision diagnostics and targeted therapies are strengthening regional demand. The region also benefits from growing clinical emphasis on early disease detection and personalized treatment approaches.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, driven by expanding healthcare infrastructure, improving access to advanced diagnostic technologies, and increasing awareness of nuclear medicine applications. Greater investment in specialized medical facilities and the adoption of modern imaging and therapeutic technologies are supporting broader regional utilization.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Imaging IntegrationGermany strengthens nuclear medicine through close integration of diagnostic imaging, radiopharmaceutical production, and clinical research. Healthcare institutions prioritize advanced imaging technologies that improve workflow efficiency and personalized patient management.
France 🇫🇷
Research-Driven Clinical AdoptionFrance supports nuclear medicine through coordinated research initiatives and expanding clinical use of targeted radiopharmaceuticals. French healthcare organizations emphasize multidisciplinary collaboration to improve diagnostic accuracy and treatment planning across specialized care settings.
Italy 🇮🇹
Hospital Network ModernizationItaly strengthens its nuclear medicine market by modernizing hospital imaging facilities and improving access to advanced radiopharmaceutical services. Italian healthcare providers continue enhancing clinical capabilities through technology upgrades and specialized medical expertise.
Japan 🇯🇵
Radiopharmaceutical Development FocusJapan continues advancing nuclear medicine by supporting innovation in radiopharmaceutical research and specialized diagnostic procedures. Japanese healthcare providers increasingly integrate targeted imaging solutions into routine clinical practice for complex disease management.
South Korea 🇰🇷
Advanced Clinical DeploymentSouth Korea expands nuclear medicine capabilities through investments in modern imaging infrastructure and domestic radiopharmaceutical development. Clinical centers increasingly adopt advanced diagnostic and therapeutic procedures to enhance precision healthcare services.
United States 🇺🇸
Clinical Innovation PipelineThe U.S. nuclear medicine market benefits from ongoing expansion of radiopharmaceutical development and advanced diagnostic imaging services. Healthcare providers continue investing in production capabilities and precision medicine applications that broaden clinical adoption.
Segment Leadership and Growth Trends
Nuclear Medicine Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Diagnostics (Largest Segment) vs Therapeutics (Fastest-Growing Segment)
Diagnostics held the dominant position in the nuclear medicine market, accounting for a 73.49% share in 2026. The segment benefits from the established use of nuclear imaging in detecting, characterizing, and monitoring a broad range of diseases, particularly cancer and cardiovascular conditions. Nuclear diagnostic procedures provide functional information that complements conventional anatomical imaging, supporting more precise disease assessment and treatment planning. Increasing emphasis on earlier diagnosis, personalized clinical decision-making, and advanced imaging capabilities continues to sustain demand for nuclear medicine diagnostics.
Therapeutics is gaining momentum as nuclear medicine increasingly expands beyond disease detection toward targeted treatment. Radiopharmaceutical therapies can deliver radiation directly to specific disease sites, offering a more selective approach to managing certain cancers and other conditions. Growing clinical interest in targeted radionuclide treatment, advances in radiopharmaceutical development, and increasing emphasis on personalized care are supporting greater adoption of therapeutic nuclear medicine and strengthening its growth potential.
End Use Segment Analysis: Hospitals (Largest & Fastest-Growing Segment)
Hospitals led the nuclear medicine market with a 57.75% share in 2026 and also represented the fastest-growing end-use segment. Their leading position reflects the broad availability of specialized imaging, radiopharmaceutical administration, diagnostic services, and multidisciplinary clinical expertise within hospital settings. Nuclear medicine is increasingly integrated into oncology, cardiology, and other specialized care pathways, allowing hospitals to use diagnostic and therapeutic procedures across complex patient needs. Expansion of advanced clinical capabilities and the growing role of precision medicine are further supporting nuclear medicine adoption within hospitals.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Diagnostics, Therapeutics | Diagnostics | Therapeutics |
| End Use | Hospitals, Diagnostic Centers, Others | Hospitals | Hospitals |
| Application | Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumor, Pulmonary Scans, Urology, Other | Urology | Urology |
Competitive Landscape and Market Positioning
Key companies in the nuclear medicine market:
1. GE HealthCare Technologies Inc. (United States)
2. Cardinal Health Inc. (United States)
3. Lantheus Holdings Inc. (United States)
4. Bracco Imaging S.p.A. (Italy)
5. Mallinckrodt plc (Ireland)
6. Eckert & Ziegler SE (Germany)
7. Nordion Inc. (Canada)
8. Curium Pharma (France)
9. Jubilant Pharmova Limited (India)
10. Eczacıbaşı-Monrol Nuclear Products Co. (Turkey)
The nuclear medicine market is expanding through advancements in radiopharmaceutical development and precision imaging technologies. Healthcare organizations are increasing focus on targeted diagnostics and therapeutic procedures that improve disease detection and treatment effectiveness. Ongoing investments in isotope production capabilities and specialized imaging systems are further supporting market evolution.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (United States) | |||||||
| Cardinal Health Inc. (United States) | |||||||
| Lantheus Holdings Inc. (United States) | |||||||
| Bracco Imaging S.p.A. (Italy) | |||||||
| Mallinckrodt plc (Ireland) | |||||||
| Eckert & Ziegler SE (Germany) | |||||||
| Nordion Inc. (Canada) | |||||||
| Curium Pharma (France) | |||||||
| Jubilant Pharmova Limited (India) | |||||||
| Eczacıbaşı-Monrol Nuclear Products Co. (Turkey). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Eden Radioisotopes | May-26 | Eden Radioisotopes submitted a construction permit application for a dedicated medical isotope production facility in New Mexico. The plant utilizes a specialized reactor concept optimized for high-yield isotope extraction, addressing domestic radiopharmaceutical supply constraints and bolstering infrastructure for targeted nuclear medicine therapies. |
| Catalyst MedTech | Apr-26 | Catalyst MedTech completed the acquisition of X3D to scale its original equipment manufacturer platform and enhance its footprint in nuclear medicine imaging. The transaction integrates specialized radiological imaging technologies into Catalyst's portfolio, optimizing diagnostic workflows and clinical software compatibility. |
| SHINE Technologies | Mar-26 | SHINE Technologies secured $240 million in a funding round led by NantWorks to accelerate the development of its nuclear medicine division. The capital will scale manufacturing infrastructure and expand production capacity for critical medical isotopes, specifically addressing supply chain vulnerabilities for SPECT imaging agents. |
| UCLA Health | Nov-25 | UCLA Health established a standalone Department of Nuclear Medicine and Theranostics to formalize its institutional focus on precision medicine. This organizational restructuring aims to integrate diagnostic imaging with targeted radiopharmaceutical therapies, accelerating clinical trials and optimizing operational workflows for oncology care. |
| University of Missouri | Apr-25 | The University of Missouri signed a phase-one agreement to construct a new research reactor dedicated to expanding domestic nuclear medicine capabilities. The specialized facility is designed to scale up the production of essential medical isotopes for cancer treatments and reinforce national radiopharmaceutical research infrastructure. |
| Sanofi | Oct-24 | Sanofi and Orano Med formed a strategic agreement to co-invest in a new entity operating under the Orano Med brand. The joint venture focuses on the discovery, design, and clinical commercialization of next-generation radioligand therapies utilizing the alpha-emitting isotope lead-212 to treat rare cancers. |
| Lantheus Holdings, Inc. | Jan-24 | Lantheus Holdings solidified its oncology pipeline by executing strategic agreements with Perspective Therapeutics, including an upfront $28 million cash payment. The deal secures an exclusive option to license a lead-212-labeled alpha-radiopharmaceutical therapy for neuroendocrine tumors and establishes co-development rights for early-stage prostate cancer treatments. |
| Bristol Myers Squibb | Dec-23 | Bristol Myers Squibb entered into a definitive agreement to acquire RayzeBio for $4.1 billion to expand its oncology portfolio. The acquisition integrates RayzeBio's pipeline of actinium-225-based radiopharmaceutical therapeutics currently in clinical trials, alongside related lutetium-177 programs, strengthening the company's long-term competitive position in targeted theranostics. |
| Novartis | Apr-23 | Novartis received U.S. FDA approval for its Milburn facility to commence commercial manufacturing of its targeted radioligand therapy, Pluvicto. The regulatory milestone significantly increases the company's automated production capacity to meet growing global demand for advanced prostate cancer treatments. |
| NorthStar Medical Radioisotopes | Jan-23 | NorthStar Medical Radioisotopes successfully advanced its proprietary production technology to manufacture molybdenum-99 without relying on enriched uranium. This operational milestone enhances supply chain resilience for technetium-99m generators and establishes a more sustainable, non-proliferation-compliant manufacturing footprint in the nuclear medicine sector. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Nuclear Medicine Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Radioisotope Supply Model | Reactor-Produced Isotopes, Cyclotron-Produced Isotopes, Generator-Based Isotopes |
| Route of Administration | Intravenous, Oral, Inhalation, Other Routes |
| Procurement Model | Direct Procurement, Group Purchasing, Distributor-Mediated Procurement |
Nuclear Medicine Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Radiopharmaceutical Pipeline Assessment |
|
| Isotope Supply Chain Resilience |
|
| Clinical Adoption Opportunity Mapping |
|
Need a different cut of the data?
Request Custom ResearchHow much is the nuclear medicine market worth?
What is the expected industry size of nuclear medicine by 2036?
How is the expansion of theranostics influencing adoption across the nuclear medicine market?
Why are reimbursement policies and government funding critical to nuclear medicine market expansion?
Why do diagnostics dominate the nuclear medicine market?
Why are hospitals the fastest-growing end-use segment in nuclear medicine?
Why does North America lead the nuclear medicine market?
What is driving Asia Pacific growth in the nuclear medicine market?
What are the key competitors in the nuclear medicine landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization